NK Cell-Targeting Strategies Come Into Their Own

Source: OncLive, April 2021

Although anticancer therapies that leverage T cells have commanded the most attention in the immuno-oncology era of the past decade, strategies based on natural killer (NK) cells have recently emerged as attractive approaches.1,2

NK cell-based adoptive cell therapies (ACTs), including genetically modified chimeric antigen receptor (CAR)-NK cells, are safer than their T cell-based counterparts and have the potential for “off-the-shelf” use.1,2 NK cell-based strategies in clinical development also include NK cells that express activating cytokines, as well as antibodies targeting receptors on the NK cell surface.

READ THE ORIGINAL FULL ARTICLE